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Abstract The fat mouse strain exhibits a late-onset obesity
syndrome associated with a mutation in the gene encoding
carboxypeptidase E (CPE). CPE plays a central role in the
biosynthesis of many regulatory peptides. Therefore, we
examined the processing of procholecystokinin (proCCK) in the
brain (neurons) and small intestine (endocrine cells) of fat/fat
mice. In the brain, bioactive CCK was markedly reduced
(7.9 þ 1.0 pmol/g in fat/fat mice vs. 82.5 þ 11.2 pmol/g in
controls), but the concentration of the CPE substrate, glycyl-
arginine-extended CCK, was elevated 105-fold. In contrast, the
concentration of bioactive CCK in intestinal endocrine cells was
unaffected. Endocrine cell processing was, nevertheless, altered
with a 33-fold increase in glycyl-arginine-extended CCK.
Interestingly, although total proCCK products were normal in
the brain they were elevated 3-fold in the intestine, indicating
that biosynthesis is upregulated in endocrine cells but not neurons
to compensate for the processing defect. These results demon-
strate that the CPE mutation differentially affects CCK
processing in these two cell types. Intestinal CCK synthesis
more closely resembles progastrin processing, suggesting the
presence of an endocrine-specific biosynthetic regulatory mech-
anism not present in neurons.
z 1998 Federation of European Biochemical Societies.
Key words: Cholecystokinin; Prohormone processing;
Carboxypeptidase E; Obesity; fat mouse
1. Introduction
The CPEfat mouse strain (fat) exhibits a slowly developing
adult-onset obesity with mild diabetes due to a genetic muta-
tion (Ser202Pro) in the peptide processing enzyme carboxypep-
tidase E (CPE), which abolishes enzyme activity [1,2]. CPE is
expressed in a variety of neurons and endocrine cells, thus, the
posttranslational processing of many peptide hormones and
neuropeptides could be altered in fat/fat mice. Regulatory
peptides are synthesized as large propeptides that undergo a
series of modi¢cations in the trans-Golgi network and secre-
tory vesicles before being released as active peptides. These
modi¢cations include endo- and exoproteolytic cleavages, sul-
fation, phosphorylation, and amidation [3^7].
CPE cleaves C-terminal basic residues during protein proc-
essing; thus, peptides requiring removal of C-terminal basic
residues for bioactivity may be de¢cient in the fat/fat mouse.
Accordingly, fat/fat mice do not process proinsulin, prodynor-
phin, proneurotensin, promelanin-concentrating hormone and
pro-opiomelanocortin properly as demonstrated by an accu-
mulation of hormone precursors and a marked decline in the
concentration of bioactive peptides [2,8^10]. Moreover, the
processing of progastrin is also a¡ected [11,12]. However, in
contrast to the other regulatory peptides examined, we have
shown that gastrin biosynthesis is upregulated to maintain
normal production of bioactive peptide [11]. It has become
increasingly di⁄cult to predict the complete range of peptides
a¡ected in the fat/fat mouse particularly since the discovery of
another carboxypeptidase, carboxypeptidase D, which may
compensate for CPE in some tissues [1,9,13].
Cholecystokinin (CCK) is a neuroendocrine peptide synthe-
sized in intestinal endocrine cells (I cells) and many neurons of
the peripheral and central nervous systems. It is closely related
to gastrin. CCK regulates a variety of physiological functions
in both the gastrointestinal tract and central nervous system.
Speci¢cally, both peripheral and central administration of
CCK dose-dependently inhibits food intake [14^16]. ProCCK
processing involves endoproteolytic cleavage by prohormone
convertases yielding a C-terminally glycyl-arginine extended
CCK, which by carboxypeptidase removal of the arginyl res-
idues exposes a glycine-extended CCK for amidation (Fig. 1).
Thus, the potential for CCK processing de¢ciencies or atten-
uated postprandial CCK release is of particular interest con-
sidering the proposed satiety function of CCK and the obese
phenotype of fat/fat mice.
Using the fat mouse as an in vivo model, we have now
tested the hypothesis that CPE is required for the maturation
of proCCK. Moreover, we examined how alterations in proc-
essing might a¡ect CCK biosynthesis di¡erentially in neurons
and intestinal endocrine cells to ameliorate the e¡ects of re-
duced maturation. Finally, we measured plasma concentra-
tions of bioactive CCK to determine if fat/fat mice respond
adequately to a meal.
2. Materials and methods
2.1. Mice and genotyping
Heterozygous fat/+ mice were purchased from The Jackson Labo-
ratory (Bar Harbor, ME, USA). Mice were housed on a 12-h light-
dark cycle and fed Purina 5008 chow ad lib. Homozygous fat/fat and
wild-type (+/+) mice were generated by intercrossing heterozygotes
and genotyping the o¡spring. Genomic DNA was prepared from
tail biopsies [17]. The fat and wild-type CPE alleles were detected
using an allele speci¢c polymerase chain reaction (PCR) assay as
previously described [11].
2.2. Tissue isolation and extraction
Adult mice 2^6 months old were anesthetized, and the brain and
small intestine (excluding duodenum) were rapidly dissected and fro-
zen in liquid nitrogen. The tissue was washed gently in phosphate
bu¡ered saline, on ice, before freezing. Tissue extracts for radioimmu-
noassay (RIA) were prepared as previously described [18]. Brie£y,
frozen tissues were boiled in water (1 ml/mg) for 20 min, homogenized
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(polytron) and centrifuged for 30 min at 10 000 rpm. The supernatants
were withdrawn and the pellets re-extracted in 0.5 M CH3COOH
(1 ml/mg), rehomogenized, incubated at room temperature for
30 min and centrifuged. The water and acid supernatants were stored
at 320‡C until RIA analysis.
2.3. Chromatography
One or two ml of extracts were applied to Sephadex G-50 super¢ne
columns (10U1000 mm), which were eluted at 4‡C with 0.02 M bar-
bital bu¡er, pH 8.4, containing 0.1% bovine serum albumin. Fractions
of 1.0 ml were collected at a rate of 4.0 ml/h. The columns were
calibrated with [125I]albumin (void volume), human CCK-33, -22, -8
(sulfated) and with 22NaCl (total volume). The elutions were moni-
tored with sequence-speci¢c radioimmunoassays as described below.
2.4. Radioimmunoassay
A library of sequence speci¢c antibodies against proCCK was used
to measure the di¡erent forms of bioactive CCK and processing in-
termediates (Fig. 1). The sum of carboxyamidated and O-sulfated
CCKs (CCK-8, -22, -33, -39, -58, and -83) were measured using the
CCK-speci¢c antiserum no. 92128, with [125I]CCK-8 as tracer and
CCK-8 as standard [19]. Antibody no. 92128 binds all carboxyami-
dated and O-sulfated forms of CCK (i.e. bioactive) with equimolar
a⁄nity irrespective of size and sulfation. Crossreactivity with homol-
ogous gastrin peptides is negligible [19]. Glycine-extended intermedi-
ates of CCK were measured using antiserum no. 3208 with
[125I]glycine-extended CCK-8 as tracer and glycine-extended CCK-8
as standard [20]. Glycine-arginine-extended intermediates were meas-
ured using antiserum no. 3208 following enzymatic pretreatment with
carboxypeptidase B. To measure all precursor forms of CCK, samples
were pretreated with trypsin and carboxypeptidase B followed by RIA
with antiserum no. 3208, as described previously [20]. Carboxypep-
tidase B mimics the e¡ect of CPE, while trypsin mimics the e¡ects of
prohormone convertases. To con¢rm that our measurements ac-
counted for only CCK peptides, control measurements of gastrin pep-
tides were performed with a gastrin-speci¢c RIA using the antibody
no. 2604 [21].
2.5. RNA analysis
Tissues for RNA analysis were dissected from four fat/fat mice and
four wild-type mice following an overnight fast. Total RNA was ex-
tracted from frozen tissue by a guanidine thiocyanate homogeniza-
tion-CsCl centrifugation method [22]. For Northern blot analysis,
total brain and small intestine RNA samples (10 Wg) were electro-
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Fig. 1. Diagrammatic presentation of the co- and posttranslational modi¢cation of preprocholecystokinin (proCCK). Activation of the CCK
amidation site occurs via a series of carboxy-terminal cleavages and modi¢cations. Endoproteolytic cleavage by prohormone convertases produ-
ces the carboxypeptidase E substrate (R1-Phe-Gly-Arg). Carboxypeptidase E then acts in secretory granules to remove the C-terminal arginine
residue yielding glycine-extended CCK (R1-Phe-Gly). Carboxyamidation of glycine-extended CCK by a-amidating mono-oxygenase results in
the production of bioactive CCK (R1-Phe-NH2). Concomitant N-terminal cleavage by prohormone convertases produces pro- and bioactive
CCK of varying sizes (e.g. CCK-83, CCK-33, CCK-22, etc.). A library of sequence-speci¢c antibodies was used in combination with in vitro
protease treatments to measure bioactive CCK and various precursor peptides, as described in Section 2.
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phoresed in agarose gels containing 2.2 M formaldehyde and trans-
ferred to Zeta-Probe nylon membrane (Bio-Rad). Probes were 32P-
labeled and hybridized to ¢lters as previously described [23]. Final
wash concentrations were 0.5U SSC (0.075 M NaCl, 7.5 mM triso-
dium citrate, pH 7.0) and 0.1% SDS at 60‡C. Imaging and quantita-
tion were performed on a GS-250 Molecular Imager (Bio-Rad). The
CCK probe was a 0.8-kb BglII fragment containing exon 3 isolated
from a genomic clone described by Vitale et al. [24]. After hybrid-
ization, ¢lters were stripped and rehybridized with a mouse ribosomal
protein L32 (rpL32) probe [25] to control for RNA loading.
2.6. Plasma hormone measurements
To examine changes in plasma CCK concentrations in response to
feeding, mice were fasted for 24 h prior to blood collection by retro-
orbital bleeding. A second group of mice was fasted and then refed
for 40 min prior to bleeding. Blood was collected into tubes contain-
ing 10 mM EDTA. Plasma concentrations of bioactive CCK
(carboxyamidated and O-sulfated) were measured by RIA using anti-
body no. 92128 as previously described [19].
2.7. Statistics
Statistical analysis was carried out using an unpaired t-test with the
SYSTAT software. All values are expressed as means þ S.E.M.
3. Results
3.1. Brain proCCK processing
The concentrations of sulfated carboxyamidated CCK in
the brain were 10-fold lower in fat/fat mice compared to
wild-type controls (Table 1). To determine the e¡ect of the
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Fig. 2. Gel chromatography of brain extracts from CPE-mutant fat/fat mice (left) and wild-type control mice (right). The upper panels (A and
C) show the elution of carboxyamidated and O-sulfated CCK as measured using Ab. no. 92128 (b^b), and glycine-extended CCK (measured
using Ab. no. 3208, a^a). The lower panels (B and D) show the elution of glycyl-arginine-extended CCKs (measured using Ab. no. 3208 after
carboxypeptidase B treatment, b^b) and further C-terminally extended gastrins (measured using Ab. no. 3208 after trypsin and carboxypep-
tidase B treatment, a^a). The peaks are identi¢ed relative to the elution position of the CCK peptides used for calibration.
Table 1
ProCCK products in fat/fat and wild-type mice (pmol/g tissue (wet weight); mean þ S.E.M.)
CCK peptides Brain Small intestine
fat/fat Wild-type fat/fat Wild-type
Carboxyamidated 7.9 þ 1.0 82.5 þ 11.2 18.3 þ 2.1 18.3 þ 4.4
Glycine-extended 7.4 þ 0.5 11.0 þ 1.2 11.4 þ 1.7 3.3 þ 0.3
Glycyl-arginine-extended 69.0 þ 9.8 0.66 þ 0.7 29.3 þ 2.3 0.9 þ 0.5
Further C-terminally extended 34.5 þ 3.6 19.5 þ 1.8 13.2 þ 3.1 4.1 þ 0.9
Total proCCK product 118.8 113.7 72.2 26.6
N = 4 mice/group.
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CPE mutation on further proCCK processing in cerebral neu-
rons, we measured the concentrations of processing intermedi-
ates (Fig. 1). The concentration of glycyl-arginine-extended
CCK, the CPE substrate, was elevated 105-fold in fat/fat
mice (69.0 þ 9.8 vs. 0.66 þ 0.7 pmol/g), whereas the concentra-
tion of glycine-extended CCK decreased slightly (7.4 þ 0.5 vs.
11.0 þ 1.2 pmol/g). The concentrations of further C-terminally
extended products almost doubled in fat/fat mice (Table 1).
Summing up all forms of CCK (bioactive and precursor pep-
tides = total proCCK products), fat/fat mouse brains con-
tained an equivalent amount of total proCCK products
compared to wild-type controls (Table 1).
Gel chromatography revealed additional di¡erences in the
endoproteolytic processing of proCCK in fat/fat mice (Fig. 2).
Glycine-extended and further C-terminally extended CCKs
were less e⁄ciently cleaved at N-terminal processing sites in
fat/fat mice, leading to a smaller fraction of short molecular
forms of CCK. This molecular pattern suggests that CPE
activity in£uences endoproteolytic prohormone convertase
cleavage (Table 1, Figs. 1 and 2).
3.2. Intestinal proCCK processing
Unlike the brain, the concentration of bioactive CCK in the
gut was identical in fat/fat mice and wild-type controls (Table
1). Upon further analysis of processing intermediates we
found that the concentration of glycyl-arginine-extended
CCK, the CPE substrate, was elevated 33-fold in fat/fat
mice (29.3 þ 2.3 vs. 0.9 þ 0.5 pmol/g). Similarly, the concentra-
tions of glycine-extended CCK and further C-terminally ex-
tended CCK increased approximately 3-fold in intestinal ex-
tracts from fat/fat mice compared to wild-type controls (Table
1). Summing up the total proCCK products, the small intes-
tine from fat/fat mice contained nearly three times more total
proCCK products compared to wild-type controls (Table 1).
Gel chromatography revealed similar patterns of carboxy-
amidated CCK in fat/fat compared to controls, with only
minor di¡erences occurring in the N-terminal proteolytic
processing of proCCK in fat/fat mice (Fig. 3). Glycyl-argi-
nine-extended CCK was present in chromatographically de-
tectable forms only in fat/fat mice, where they constituted a
mixture of long and short forms. The molecular pattern sug-
gests that CPE in£uences endoproteolytic prohormone con-
vertase cleavage only marginally in the small intestine in con-
trast to the greater accumulation of longer proCCK forms
observed in the brain (Figs. 2 and 3).
3.3. Plasma CCK
Fasting plasma concentrations of bioactive CCK in fat/fat
mice were not signi¢cantly altered compared to wild-type con-
trols (Fig. 4). To examine whether fat/fat mice exhibit the
normal postprandial rise in CCK, we also measured CCK
concentrations in plasma after refeeding. In wild-type mice
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Fig. 3. Gel chromatography of small intestinal extracts from the CPE-mutant fat/fat mice (left) and wild-type control mice (right). The upper
panels (A and C) show the elutions of carboxyamidated and O-sulfated CCK (measured using Ab. no. 92128, b^b) and glycine-extended
CCKs (measured using Ab. no. 3208, a^a). The lower panels (B and D) show the elution of glycyl-arginine-extended CCKs (measured using
Ab. no. 3208 after carboxypeptidase B treatment, b^b) and further C-terminally extended CCKs (measured using Ab. no. 3208 after trypsin
and carboxypeptidase B treatment, a^a). The peaks are identi¢ed relative to the elution position of the CCK peptides used for calibration.
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CCK concentrations signi¢cantly increased 40 min after re-
feeding. However, this response was attenuated in fat/fat mice.
Postprandial concentrations of CCK in fat/fat mice did not
rise signi¢cantly and were 34% lower than control mice
(P6 0.01).
3.4. CCK mRNA levels
CCK mRNA levels measured by Northern blot analysis
were unchanged in both the brain and the small intestine of
fat/fat mice (Fig. 5). This indicates that the 3-fold increase in
intestinal proCCK products is not a result of increased gene
expression.
4. Discussion
This study displays remarkable di¡erences in the way car-
boxypeptidase E de¢ciency a¡ects the biosynthesis of CCK in
its two major sites of expression, the brain (representing neu-
ronal synthesis) and the small intestine (representing endo-
crine synthesis).
In cerebral neurons, the synthesis of bioactive CCK is
grossly reduced, while the concentration of the total translated
proCCK product is maintained at a strictly normal level (Ta-
ble 1). A particularly striking change is the 105-fold increase
in the concentration of the CPE substrate, glycyl-arginine ex-
tended CCK (Table 1). In contrast, endocrine CCK synthesis
is a¡ected in an entirely di¡erent way. The tissue concentra-
tion of bioactive CCK is maintained at normal levels, while
the concentrations of processing intermediates are markedly
increased. Not only is the concentration of glycyl-arginine
extended CCK (the CPE substrate) elevated 33-fold, but the
levels of glycine- and further C-terminally extended CCK are
also increased (Table 1). Hence, the intestinal total proCCK
products combined are nearly 3-fold higher in the intestines of
fat/fat mice compared to controls.
The gross reduction in cerebral CCK synthesis resembles
the previously described de¢cits of insulin, neurotensin, mel-
anin-concentrating hormone, dynorphin and ACTH in CPE-
de¢cient mice [2,8^10]. All are characterized by a large reduc-
tion in bioactive peptide and the accumulation of arginine-
extended precursor forms. In contrast, CCK synthesis in in-
testinal endocrine cells (I-cells) more closely resembles gastrin
synthesis in gastric endocrine cells (G-cells). Bioactive gastrin
and intestinal CCK are both produced in normal amounts
and show elevated prohormone biosynthesis [11]. The precise
mechanism of increased biosynthesis may be di¡erent for gas-
trin and CCK since elevated gastrin biosynthesis correlates
with a 2-fold increase in gastrin mRNA [11,12], but intestinal
CCK mRNA levels do not change in fat/fat mice compared to
controls (Fig. 5). As suggested for gastrin [11], the pattern of
intestinal CCK synthesis in CPE-de¢cient mice suggests that
endocrine cells in the gastrointestinal tract have another bio-
synthetic pathway independent of CPE activity. The increased
concentrations of glycine-extended processing intermediates in
G- and I-cells further supports this hypothesis (Table 1 and
[11]). This alternative pathway likely utilizes other carboxy-
peptidases to compensate for the absence of intestinal CPE
[1,9,13].
During the preparation of this paper, Cain et al. [26] re-
ported the results of a similar study on proCCK processing in
fat/fat mice. Their conclusions generally correspond to those
presented here, however, their results deviate in several im-
portant respects. First, they measured CCK in duodenal ex-
tracts and observed a signi¢cant decrease in bioactive CCK
and no change in arginine-extended CCK, while we observed
no decrease in bioactive CCK and elevated arginine-extended
CCK in intestinal extracts. Their report did not take into
account crossreactivity with gastrin precursors in the duode-
num. Since gastrin is also synthesized in the duodenum, and
since there is a substantial increase in gastrin precursor con-
centrations [11], the analysis of duodenal CCK processing is
more di⁄cult to interpret. Second, Cain et al. [26] did not
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Fig. 4. Plasma concentrations of bioactive CCK in fasted and refed
mice. Fasted mice were food deprived for 24 h, and refed mice were
fasted then refed for 40 min before plasma collection. Open bars
represent fasted mice and solid bars represent refed mice. The mean
values and S.E.M. are expressed as pmol per liter plasma. The num-
ber of mice is shown for each group (n). *P6 0.01.
Fig. 5. CCK mRNA abundance in fat/fat mice. Displayed are the
results from Northern blot analysis of brain and small intestinal
RNA hybridized with a CCK probe from two wild-type (+/+) and
two fat/fat (f/f) mice. The top half of each panel shows hybridiza-
tion with the CCK probe, while the bottom half of each panel
shows the same ¢lters after stripping and rehybridizing with the
rpL32 probe to control for loading. Phosphoimager analysis was
used to quantitate CCK mRNA abundance in four wild-type and
four fat/fat mice as described in Section 2.
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measure the full complement of CCK precursors, which is
central to the argument for the existence of alternate biosyn-
thetic pathways in neurons and endocrine cells. Our results
also allow for a more direct comparison with the previous
report on the endocrine cell processing of gastrin and lead
us to suggest that endocrine I- and G-cells may similarly reg-
ulate prohormone biosynthesis. In addition, we have meas-
ured CCK mRNA and plasma concentrations which further
adds to our understanding of possible regulatory mechanisms
of hormone biosynthesis as well as possible physiological ef-
fects resulting from altered circulating hormone concentra-
tions (see below). Finally, it should be pointed out that our
CCK measurements in the brain are 10-fold higher than those
reported by Cain et al. [26], most likely due to di¡erent ex-
traction procedures.
Although we have shown that the concentration of bioac-
tive CCK in intestinal tissue extracts was normal, fat/fat mice
did not show the normal meal-stimulated rise in circulating
CCK. This observation is consistent with the debated sugges-
tion [8] that CPE also functions as a sorting receptor for
packaging hormones into the regulated secretory pathway.
The decrease in postprandial hormone levels nevertheless in-
dicates that the regulated secretory pathway is dysfunctional.
The lower postprandial CCK concentrations in plasma, as
well as the marked reduction in neural CCK concentrations,
suggest that CCK function is diminished in this mutant. This
is of particular interest considering the potential satiety func-
tion of CCK.
The present study does not show whether the CCK de¢-
ciency contributes to the obese phenotype of the fat mouse,
however, others have demonstrated that both exogenous and
endogenous CCK induce satiety in rodents [14^16,27]. In ad-
dition, exogenous administration of CCK produces a syner-
gistic interaction with leptin, heightening leptin’s satiety ef-
fects [28,29]. Barrachina et al. and Matson et al. [28,29]
have also demonstrated that devazepide, a CCK antagonist,
blocks leptin-induced inhibition of food intake. Therefore,
reduced CCK levels in the brain, as well as a reduction in
circulating CCK following a meal, may well contribute to
the obese phenotype in fat/fat mice.
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